

# Single Nucleotide Polymorphism of Toll-like Receptor 4 (TLR4) is Associated with Juvenile Spondyloarthritis in Croatian Population

---

Perica, Marija; Vidović, Mandica; Lamot, Lovro; Tambić Bukovac, Lana; Kapitanović, Sanja; Perić, Magdalena; Barbić, Jerko; Harjaček, Miroslav

Source / Izvornik: **Clinical Rheumatology**, 2015, 34, 2079 - 2086

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1007/s10067-015-2952-8>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:239:153096>

Rights / Prava: [Attribution 4.0 International](#)/[Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-07-23**



Repository / Repozitorij:

[Repository UHC Osijek - Repository University Hospital Centre Osijek](#)

# Single nucleotide polymorphism of toll-like receptor 4 (TLR4) is associated with juvenile spondyloarthritis in Croatian population

Marija Perica<sup>1</sup> · Mandica Vidović<sup>1</sup> · Lovro Lamot<sup>1,5</sup> · Lana Tambić Bukovac<sup>1</sup> · Sanja Kapitanović<sup>2</sup> · Magdalena Perić<sup>3</sup> · Jerko Barbić<sup>4,6</sup> · Miroslav Harjaček<sup>1,5</sup>

Received: 31 March 2015 / Revised: 21 April 2015 / Accepted: 21 April 2015 / Published online: 30 April 2015  
© International League of Associations for Rheumatology (ILAR) 2015

**Abstract** Single nucleotide polymorphisms (SNP) of toll-like and NOD-like receptors have been associated with altered receptor activity and modified production of proinflammatory cytokines leading to a number of diseases. Our aim was to determine whether SNP of TLR2 (Arg753Gln), TLR4 (Asp299Gly, Thr399Ile), and NLRP3 (Q705K) influence susceptibility to juvenile spondyloarthritis (jSpA) and juvenile idiopathic arthritis (JIA). After the DNA extraction, 26 patients with jSpA, 11 with oligoarticular, polyarticular, or systemic JIA, and 40 healthy controls were genotyped for Arg753Gln, Asp299Gly, Thr399Ile, and Q705K SNP using real-time PCR–SNP analysis. Statistically significant difference in genotype frequency for Thr399Ile SNP of TLR4 was observed in the jSpA ( $\chi^2=6.705$ ,  $p=0.035$ ) and not in the JIA group ( $\chi^2=3005$ ,  $p=0.223$ ). Regarding Asp299Gly SNP, no significant difference in genotype frequency was found; however, allele frequency was significant in both jSpA and JIA patients. No significant difference in genotype or allele frequency was observed for Arg735Gln and Q705K SNP. The399Ile polymorphism of TLR4 may be responsible for altered immune response to microbial infection in variant car-

riers and represent a mechanism of triggering overproduction of proinflammatory cytokines and long-term inflammation in jSpA. SNP of TLR2, NLRP3, and TLR4 (Asp299Gly) were not associated with jSpA or JIA.

**Keywords** Juvenile idiopathic arthritis · Juvenile spondyloarthritis · Single nucleotide polymorphism · Toll-like receptor

## Introduction

Juvenile spondyloarthritis (jSpA) is a group of inflammatory disorders affecting children under 16 years of age, clinically characterized by enthesitis and arthritis, with a prevalence of 0.7–1.2 % [1]. This family of disorders comprises of the following: ankylosing spondylitis, reactive arthritis, psoriatic arthritis, arthritis associated with inflammatory bowel disease, undifferentiated SpA, and juvenile form of SpA. According to the International League of Associations for Rheumatology (ILAR) criteria, spondyloarthritis is classified as enthesitis-

✉ Marija Perica  
marija\_perica@hotmail.com  
Mandica Vidović  
vidovicmand@yahoo.com  
Lovro Lamot  
lovro.lamot@gmail.com  
Lana Tambić Bukovac  
lanabukovac@gmail.com  
Sanja Kapitanović  
kapitan@irb.hr  
Magdalena Perić  
magdalena0706@gmail.com

Jerko Barbić  
jerko.barbic@mefos.hr  
Miroslav Harjaček  
miroslav.harjacek@zg.t-com.hr

<sup>1</sup> Department of Pediatric Rheumatology, Children's Hospital Srebrnjak, Srebrnjak 100, 10000 Zagreb, Croatia  
<sup>2</sup> Ruder Bošković Institute, Zagreb, Croatia  
<sup>3</sup> Institute for Public Health, Osijek, Croatia  
<sup>4</sup> Clinical Hospital Centre Osijek, Osijek, Croatia  
<sup>5</sup> School of Medicine, University of Zagreb, Zagreb, Croatia  
<sup>6</sup> School of Medicine, University of Osijek, Zagreb, Croatia

related arthritis or psoriatic arthritis [2]. Key factors in the pathogenesis of these disorders are genetic background, immune system disturbances, and environmental factors; however, their exact role has not been completely clarified [3]. Genetic background mostly refers to HLA B27 positivity, which varies in different types of jSpA (the highest proportion of HLA B27 positivity is found in ankylosing spondylitis and the lowest in undifferentiated jSpA) [4, 5]. The study by Lamot et al. indicates that jSpA could be a polygenic disease with a possible malfunction in antigen recognition and activation of immunological response, migration of inflammatory cells, and regulation of the immune system [3]. Bacterial infection is an environmental factor associated with jSpA, especially with reactive arthritis. Arthrogenic bacteria such as *Salmonella*, *Yersinia*, and *Shigella* trigger disease in about 80 % of patients with reactive arthritis [6–8]. Additional bacteria have been investigated in patients with jSpA; *Chlamydia trachomatis*, *Mycobacterium tuberculosis*, *Borrelia burgdorferi*, and *Mycoplasma pneumoniae* [9–11]. Both parts of the immune system, adaptive and innate immunity, are involved in the pathogenesis of the disease. Toll-like receptors (TLR) and NOD-like receptors (NLR), as a part of the innate immune system, are initiators of the immune response after invasion of microorganisms or following the release of endogenous molecules as a result of necrosis, injury, or lysosomal damage. Although they connect key factors of the pathogenesis of jSpA, their role has not been thoroughly investigated.

TLRs comprise a family of transmembrane proteins which play a key role in microbial recognition and regulation of innate immune response. So far, ten members of the TLR family have been described in humans. Even though toll proteins share a similar structure, each TLR interacts with a different combination of adapter proteins and activates various transcription factors such as NF- $\kappa$ B, activating protein-1, and interferon regulatory factors, driving a specific immune response [12, 13]. Over the past several years, studies have identified a number of common TLR single nucleotide polymorphisms (SNP) which are the result of single nucleotide alteration in the genome sequence. Many SNPs of TLRs have no effect on cell function; however, some of them modify cellular immune response and can be associated with susceptibility to a spectrum of diseases [14].

TLR2, among the TLRs, recognizes the most diverse set of pathogens. Currently, 24 polymorphisms within the human TLR2 are described, among which Arg753Gln is one of the most common. [15] Arg753Gln has been associated with an increased risk of restenosis after percutaneous transcatheter angioplasty [16], an increased risk of acute rheumatic fever [17], and risk of CMV infection after liver transplantation [18], as well as susceptibility to a number of other infections.

TLR4 is involved in the recognition of lipopolysaccharide (LPS) of Gram negative bacteria, and it interacts with heat-shock proteins [19], fragments of hyaluronic acid [20], and

fibronectin [21]. The role of Asp299Gly and Thr399Ile SNP has been studied both in infectious and noninfectious diseases such as inflammatory bowel disease, asthma, autoimmune diseases, and cancer [22, 13, 23].

NLRs are intracellular receptors, capable of recognizing microbial invasion and intracellular molecules associated with cell injury [24]. After the signal is sensed by the LRR domain, unfolding of NLRP3 enables the effector domain to recruit ASC (apoptosis-associated speck-like protein containing caspase recruitment domain family member 8 (CARD)) and the enzyme caspase, forming a cytoplasmic complex known as the inflammasome. Active caspase 1 is responsible for processing precursors of proinflammatory cytokines IL-1 and IL-18 into their active forms. Adequate downstream signaling results in efficient host defense; however, excess activity and overproduction of proinflammatory cytokines contribute to a number of diseases. Mutations in the NACHT domain of NLRP3 are responsible for cryopyrin-associated periodic syndromes (CAPS); familial cold autoinflammatory syndrome (FCAS), Muckle–Wells syndrome (MWS), and neonatal onset multi-systemic inflammatory disease (NOMID) [25, 26]. Several studies have associated SNP polymorphism of NLRP3 (Q705K) with various diseases including Crohn's [27] and celiac disease [28], abdominal aortic aneurysms [29], diabetes type I [30], and rheumatoid arthritis [31].

So far, the role of the most common SNP of TLR2, TLR4, and NLRP3 in patients with juvenile spondyloarthropathies has not been revealed. To our knowledge, this is the first study to investigate the relationship between Arg753Gln, Asp299Gly, Thr399Ile, Q705K polymorphisms, and susceptibility to jSpA and JIA.

## Materials and methods

**Subjects** The study population comprised of patients diagnosed with juvenile spondyloarthritis or juvenile idiopathic arthritis at the Children's Hospital Srebrnjak, Department of Rheumatology, Zagreb, Croatia and control group of healthy blood donors. Samples were collected from 26 patients diagnosed with jSpA, 11 patients diagnosed with oligoarticular, polyarticular, or systemic form of JIA and 40 healthy individuals as the control group. All patients included met the ILAR criteria for jSpA or JIA and had not been treated with disease modifying antirheumatic drugs (DMARD) or biologic agents prior to the study enrollment. Patients diagnosed with reactive arthritis were not included in the study.

Demographics, clinical data, and blood samples were collected from the patients fulfilling criteria for study enrollment. Informed consent was obtained from each participant/participants' parents. The study was approved by the Children's Hospital Srebrnjak Ethics committee and conducted according to the guiding principles of the World Medical Association

Declaration of Helsinki of 1975, as revised in 2000 and Good Clinical Practice.

**Methods** Three common polymorphisms of TLR2 (Arg753Gln) and TLR4 (Asp299Gly, Thr399Ile) were investigated in collected blood samples of 26 jSpA, 11 JIA patients, and 40 healthy controls. JSpA and JIA patients were additionally genotyped for NLRP3 (Q705K) polymorphism.

### DNA isolation

Genomic DNAs were isolated from peripheral EDTA blood of patients using proteinase K (Macherey-Nagel, Germany) digestion followed by phenol chloroform extraction.

### Real-time PCR genotyping

Real-time PCR–SNP analysis of TLR4 Asp299Gly (rs4986790), TLR4 Thr399Ile (rs4986791), and NLRP3 Q705K (rs35829419) was performed using an ABI PRISM 7300 SDS (Applied Biosystems) and predeveloped TaqMan SNP genotyping assays (Applied Biosystems) according to the manufacturer's instructions. TLR2 (rs5743708) SNPs were analyzed using LightMix (Tib MolBiol, Germany), LightCycler DNA Master Hybridization Probes (Roche Diagnostics GmbH, Germany), and LightCycler Instrument v 1.5 (Roche, Germany). Polymorphisms of the TLR2 were determined using specific melting point ( $T_m$ ) of A for the mutant and G for the wild type in the channel F2 of the LightCycler Instrument according to the manufacturer's instructions.

For quality control, 15 % of randomly selected samples of both cases and control were re-analyzed the second time, without finding any discrepancies. Control samples covering four possible SNP genotypes and no template control were run in parallel with tested samples in each experiment.

**Statistical analysis** Significant differences in genotype and allele frequencies of TLR4, TLR2, and NLRP3 SNPs between jSpA, JIA, and control group were determined using  $\chi^2$  test. All SNPs were tested for Hardy–Weinberg equilibrium. The magnitude of association was expressed as odds ratio with

95 % confidence interval. A  $p$  value of  $<0.05$  was considered statistically significant. Statistical analysis was performed using STATISTICA for Windows, version 7.1 (StatSoft, Inc., Tulsa, OK, USA).

### Results

The study population consisted of 77 participants, 26 diagnosed with jSpA, 11 diagnosed with JIA (either oligoarthritis, polyarthritis, or systemic arthritis), and 40 healthy controls. The mean age of participants in groups were as follows:  $15.37 \pm 4.2$  for jSpA,  $11.68 \pm 4.8$  for JIA and  $41 \pm 12$  in the control group (Table 1.) The genotype and allele distribution in both groups of patients and controls is given in Table 2.

#### Asp299Gly TLR4 polymorphism

In the JIA patient group, all participants were homozygous for the wild type allele of TLR4 Asp299Gly polymorphism. There were three heterozygous and no homozygous variant allele carriers in the jSpA group. In the control group, both heterozygous (two participants) and homozygous variant allele carriers (six participants) were observed. There was no significant difference in genotype frequency between controls and both groups of patients. A statistically significant difference was observed in variant allele frequency when comparing both groups of patients with controls (jSpA  $\chi^2=3.865$ ,  $p=0.049$ , JIA  $\chi^2=4.463$ ,  $p=0.035$ ) (Table 2.).

#### Thr399Ile TLR4 polymorphism

All JIA patients were homozygous for the wild type allele of TLR4 Thr399Ile polymorphism. In the jSpA group, six heterozygous carriers and no homozygotes of variant allele were observed; while in the control group, both homozygous variant allele carriers (six participants) and heterozygotes carriers (three participants) were observed. Statistical analysis revealed significant difference in genotype frequency for Thr399Ile polymorphism in the jSpA group in comparison with controls ( $\chi^2=6.705$ ,  $p=0.035$ ). No significant difference was observed for genotype frequency in the JIA group; however, allele frequency was significant.

**Table 1** Characteristics of patients with jSpA, JIA, and controls

	jSpA	JIA	Controls
Patients, $n$	26	11	40
Mean age	$15.37 \pm 4.2$	$11.68 \pm 4.8$	$41 \pm 12$
Male gender (%)	38.46 %	18.18 %	60 %
HLA B27 positivity (N/N of genotyped patients)	20/25	1/3	
HLA B7 positivity (N/N of genotyped patients)	8/25	1/3	
HLA B27/B7 positivity (N/N of genotyped patients)	6/25	0/3	

**Table 2** Allele and genotype frequencies of the Asp299Gly and Thr399Ile TLR4, Arg735Gly TLR2, and Q705K NLRP3 polymorphism in jSpA, JIA, and the control group

	Control group		jSpA		Statistics	JIA		Statistics
	<i>n</i>	%	<i>n</i>	%		<i>n</i>	%	
TLR4 (Asp299Gly) genotype								
AA	32	80.0	23	88.46	$\chi^2=4.925$	11	100	$\chi^2=2.609$
AG	2	5.0	3	11.54	$p=0.085$	0	0	$p=0.271$
GG	6	15.0	0			0	0	
Allele					$\chi^2=3.865$			$\chi^2=4.463$
A	66	82.5	49	94.23	$p=0.049$	22	100	$p=0.035$
G	14	17.5	3	5.77	OR=0.289 (95 % CI, 0.079–1.06)	0	0	OR=0.021 (95 % CI, 0.000–10.97)
TLR4 (Thr399Ile) genotype								
CC	31	77.5	20	76.92	$\chi^2=6.705$	11	100	$\chi^2=3.005$
CT	3	7.5	6	23.08	$p=0.035$	0	0	$p=0.223$
TT	6	15.0	0	0		0	0	
Allele					$\chi^2=1.225$			$\chi^2=4.6$
C	65	81.25	46	88.46	$p=0.269$	22	100	$p=0.032$
T	15	18.75	6	11.54	OR=0.565 (95 % CI, 0.204–1.566)	0	0	OR=0.020 (95 % CI, 0.000–10.07)
TLR2 (Arg735Gly) genotype								
GG	38	95.0	17	94.4	$\chi^2=0.01$	10	100	$\chi^2=0.52$
GA	2	5.0	1	5.6	$p=0.995$	0	0	$p=0.771$
AA	0		0	0		0	0	
Allele					$\chi^2=0.008$			$\chi^2=0.314$
G	78	97.5	35	97.2	$p=0.931$	20	100	$p=0.576$
A	2	2.5	1	2.8	OR=1.114 (95 % CI, 0.098–12.7)	0	0	OR=0.195 (95 % CI, 0.000–113.8)
NLRP3 (Q705K) genotype								
CC			24	92.3		9	81.8	$\chi^2=0.882$
CA			2	7.7		2	18.2	$p=0.348$
AA			0	0		0	0	
Allele								$\chi^2=0.832$
C			50	96.2		20	90.9	$p=0.362$
A			2	3.8		2	9.1	OR=0.4 (95 % CI, 0.053–3.037)

### Arg735Gln TLR2 polymorphism

No homozygotes for the variant allele were found in all three groups. One heterozygote carrier was found in the jSpA group and two in the control group. No significant difference in allele or genotype frequency was observed among groups.

### Q705K NLRP3 polymorphism

Additional analysis of Q705K polymorphism of NLRP3 was done in samples of JIA and jSpA patients; however, due to a small sample size of controls, the same analysis could not be performed in the control group. There were no homozygotes for the variant allele in any of the groups, and only two participants from each group had heterozygous genotype. The difference in allele and genotype frequency was not statistically significant.

### Discussion

The aim of our study was to investigate whether polymorphisms of TLR2, TLR4, and NLRP3 influence susceptibility to JIA and jSpA. We have found a statistically significant correlation between polymorphism of TLR4 Thr399Ile and susceptibility to jSpA. Similar correlation was not found for JIA. Our results differ from Myles et al. [32] who have found a lack of association for both polymorphisms of TLR4 in patients with enthesitis-related arthritis in the Indian population. Lack of correlation of TLR4 polymorphisms in JIA patients has been previously reported by Lamb et al. [33] on the UK population. Previously mentioned two studies are among a few rare studies in the pediatric population. This is, to our knowledge, the first study on TLR polymorphisms in children of European origin with jSpA.

Studies investigating the role of TLR polymorphisms in an adult population of different ethnic background diagnosed with ankylosing spondylitis (AS), rheumatoid arthritis (RA), and reactive arthritis (ReA) have found opposite results. Van der Paard et al. [34] reported a lack of association of TLR4 polymorphism (A896G) with AS in the Dutch population, which was confirmed by Gergely et al. [35] for Asp299Gly and Thr399Ile polymorphism in the Hungarian population, Adam et al. [36] in the UK population, and by Na et al. [37] in the Korean population. On the contrary, Snelgrove et al. [38] found minor allele frequency of TLR4 variant to be statistically significant in the AS population and have emphasized necessity for larger studies.

A similar discrepancy regarding the association of TLR4 polymorphisms and disease susceptibility has been described for RA. Radstake et al. [15] found a protective role of Asp299Gly in a RA population from the Netherlands while other studies from the UK (Kilding et al.) [39], Spain (Sanchez et al.) [40], (Alvarez-Rodriguez et al.) [41], and France (Jean et al.) [42] did not reveal any correlation of TLR4 or TLR2 polymorphisms with susceptibility to RA.

Conflicting results could be explained by variation of polymorphism presence in different ethnic groups. Absence of TLR polymorphism in the Asian population has been confirmed by several studies [37, 43]. Differences in TLR SNP distribution among ethnic groups has also been noticed in inflammatory bowel disease studies (IBD) [44–47]. By analyzing the TLR polymorphism presence in 2491 individuals from Africa, Asia, and Europe, Ferweda et al. [48] showed that Asp299Gly and Thr399Ile polymorphism have unique distribution in each continent. African population showed a high prevalence of Asp299Gly allele (10–18 %), while a population from Asia was practically missing TLR4 polymorphisms. Allele frequency among Indo-European individuals was 3–7 %. The clustering pattern is related to out-of-Africa migration and local environmental conditions, infectious pressure [48]. However, a larger analysis of the different ethnic groups should reveal whether described discrepancies regarding susceptibility to RA and AS are the result of different ethnic background, or whether the role of TLR receptors is different for each rheumatologic disease and additionally is different for children in comparison with adults.

Although the genotype frequency for TLR4 (Asp299Gly) was not statistically significant for the jSpA group in our research ( $\chi^2=4.925$ ,  $p=0.085$ ), a large sample size should be estimated to elucidate whether the Asp299Gly polymorphism, as well as Thr399Ile, influence susceptibility to JIA. We did not find correlation between genotype frequencies of both TLR4 polymorphisms with JIA.

As it is postulated that pathogen exposure plays an important role not only in the pathogenesis of spondyloarthropathies (SpA), especially reactive arthritis and ankylosing spondylitis, but also jSpA, polymorphisms of TLR4 could be the

underlying reason for altered immune response to pathogen invasion resulting in overproduction of inflammatory cytokines and consequently resulting in predisposition to spondyloarthropathy development in susceptible individuals. Increased expression of TLR4 on mononuclear cells of peripheral blood and synovial tissue has been previously reported in patients with SpA [49]. Furthermore, linkage of TLR polymorphisms with the disease susceptibility has been reported for inflammatory bowel disease which is present in about two thirds of patients with SpA as a subclinical form of gut inflammation [50]. Inflammatory changes in the gut have been found in 65 % patients with undifferentiated SpA, 90 % of ReA patients, and 60 % of AS patients [51].

Currently, there are two theories explaining the link between the connection of intestinal and joint inflammation. The first refers to intestinal activated lymphocyte or macrophage movement disorder [32], while activated lymphocyte expressing  $\alpha4\beta7$  i  $\alpha E\beta7$  [42, 40] adhesive molecules and macrophages with CD163 receptor, suggesting their origin from intestinal mucosa, have been discovered in synovial tissue of patients with spondyloarthritis [52]. The second theory suggests the overproduction and constant exposure to high levels of TNF $\alpha$  affecting synovial fibroblast and intestinal myofibroblast, leading to inflammation development [53].

Our results suggest that polymorphism of TLR2 (Arg735Gln) is not associated with jSpA or JIA. Lack of correlation between TLR2 polymorphisms and ERA was also reported by Myles et al. [53] Previous studies found no correlation of Asp753Gln SNP with RA [54], gout [55], Behçet's disease [56], rheumatic heart disease [57], or development of secondary amyloidosis in patients with Familial Mediterranean Fever (FMF) [58]. However, it may affect the severity of FMF [59].

As the cascade of microbial recognition involves both transmembrane and intracellular receptors, we additionally screened our patient population (JIA and jSpA patients) for Q705K polymorphism of NLRP3 and found no significant correlation in either group. A literature search revealed only one report on NLRP3 SNP by Yang et al. [56] in the pediatric population (of Taiwanese origin) which indicated that OR2B11 SNP might contribute to the pathophysiology of JIA. We found no other research in the pediatric population. Studies in the adult population revealed no susceptibility to AS development in carriers of Q705K variant, but C10X SNP seem to influence susceptibility in the same group of Swedish AS patients. Healthy individuals with Q705K and C10X SNP had increased levels of IL1 $\beta$  and IL33, while carriers with only one of the mentioned SNP had normal cytokine levels [58]. A functional in vitro study in a human monocyte cell line showed increased production of IL-1 $\beta$  and IL-18 by cells expressing Q705K variant in comparison with wild type cells, thereby demonstrating the possible effect of SNP in elevating the basal state of the innate immune response [59].

The limitations of our study lay in the small sample size and inability to perform NLRP3 SNP analysis in the control patient group. Our results suggesting the lack of susceptibility of variant carriers of NLRP3 to jSpA and JIA development should be confirmed in a larger study.

In conclusion, genotype frequency The399Ile was statistically significant in patients with jSpA in comparison with the control population. Similar correlation was not found for JIA patients. We have not found any correlation of Asp299Gly, Arg735Gln, or Q705K SNP with jSpA or JIA. The399Ile polymorphism may be responsible for altered immune response to microbial infection in variant carriers and represent a mechanism of triggering overproduction of proinflammatory cytokines and long term inflammation in jSpA. Our presumption is that the locus of minor resistantiae is the gut and lack of adequate cleavage of bacteria in the gut leads to sub-clinical gut inflammation typical for jSpA patients.

**Disclosures** None.

## References

- Rutkowska-Sak L, Slowinska I, Zuber Z (2010) Juvenile spondyloarthropathies. *Ann Acad Med Stetin* 56(1):29–33
- Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol* 31(2):390–392
- Lamot L, Borovecki F, Tambic Bukovac L, Vidovic M, Perica M, Gotovac K, Harjacek M (2014) Aberrant expression of shared master-key genes contributes to the immunopathogenesis in patients with juvenile spondyloarthritis. *PLoS One* 9(12):e115416. doi:10.1371/journal.pone.0115416
- Silva-Ramirez B, Vargas-Alarcon G, Granados J, Burgos-Vargas R (2005) HLA antigens and juvenile onset spondyloarthritis: negative association with non-B27 alleles. *Clin Exp Rheumatol* 23(5):721–723
- Harjacek M, Margetic T, Kerhin-Brkljacic V, Martinez N, Grubic Z (2008) HLA-B\*27/HLA-B\*07 in combination with D6S273-134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. *Clin Exp Rheumatol* 26(3):498–504
- Leirisalo-Repo M, Helenius P, Hannu T, Lehtinen A, Kreula J, Taavitsainen M, Koskimies S (1997) Long-term prognosis of reactive salmonella arthritis. *Ann Rheum Dis* 56(9):516–520
- Townes JM, Deodhar AA, Laine ES, Smith K, Krug HE, Barkhuizen A, Thompson ME, Cieslak PR, Sobel J (2008) Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study. *Ann Rheum Dis* 67(12):1689–1696. doi:10.1136/ard.2007.083451
- Gaston JS (2005) Shigella induced reactive arthritis. *Ann Rheum Dis* 64(4):517–518. doi:10.1136/ard.2004.030395
- Harjacek M, Ostojic J, Djakovic Rode O (2006) Juvenile spondyloarthropathies associated with mycoplasma pneumoniae infection. *Clin Rheumatol* 25(4):470–475. doi:10.1007/s10067-005-0085-1
- Pacheco-Tena C, Alvarado De La Barrera C, Lopez-Vidal Y, Vazquez-Mellado J, Richaud-Patin Y, Amieva RI, Llorente L, Martinez A, Zuniga J, Cifuentes-Alvarado M, Burgos-Vargas R (2001) Bacterial DNA in synovial fluid cells of patients with juvenile onset spondyloarthropathies. *Rheumatology (Oxford)* 40(8):920–927
- Braun J, Doring E, Wu P, Heesemann J, Treharne J, Eggens U, Sieper J (1993) Synovial cellular immune response to bacterial pathogens in patients with chronic juvenile arthritis. *Z Rheumatol* 52(4):201–209
- Lorenz E, Hallman M, Marttila R, Haataja R, Schwartz DA (2002) Association between the Asp299Gly polymorphisms in the toll-like receptor 4 and premature births in the Finnish population. *Pediatr Res* 52(3):373–376. doi:10.1203/00006450-200209000-00011
- Wetzler LM (2003) The role of toll-like receptor 2 in microbial disease and immunity. *Vaccine* 21(Suppl 2):S55–S60
- von Aulock S, Schroder NW, Traub S, Gueinzus K, Lorenz E, Hartung T, Schumann RR, Hermann C (2004) Heterozygous toll-like receptor 2 polymorphism does not affect lipoteichoic acid-induced chemokine and inflammatory responses. *Infect Immun* 72(3):1828–1831
- Radstake TR, Franke B, Hanssen S, Netea MG, Welsing P, Barrera P, Joosten LA, van Riel PL, van den Berg WB (2004) The toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. *Arthritis Rheum* 50(3):999–1001. doi:10.1002/art.20114
- Hamann L, Gomma A, Schroder NW, Stamme C, Glaeser C, Schulz S, Gross M, Anker SD, Fox K, Schumann RR (2005) A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. *J Mol Med (Berl)* 83(6):478–485. doi:10.1007/s00109-005-0643-7
- Berdeli A, Celik HA, Ozyurek R, Dogrusoz B, Aydin HH (2005) TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. *J Mol Med (Berl)* 83(7):535–541. doi:10.1007/s00109-005-0677-x
- Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR (2007) Relationship between toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. *Clin Infect Dis* 44(10):1315–1320. doi:10.1086/514339
- Ohashi K, Burkart V, Flohe S, Kolb H (2000) Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. *J Immunol* 164(2):558–561
- Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC (2002) Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. *J Exp Med* 195(1):99–111
- Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd (2001) The extra domain A of fibronectin activates toll-like receptor 4. *J Biol Chem* 276(13):10229–10233. doi:10.1074/jbc.M100099200M100099200
- Misch EA, Hawn TR (2008) Toll-like receptor polymorphisms and susceptibility to human disease. *Clin Sci (Lond)* 114(5):347–360. doi:10.1042/CS20070214
- Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, Keser I, Coskun M, Cilli A, Yegin O (2004) The Arg753Gln polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. *Eur Respir J* 23(2):219–223
- Kingsbury SR, Conaghan PG, McDermott MF (2011) The role of the NLRP3 inflammasome in gout. *J Inflamm Res* 4:39–49. doi:10.2147/JIR.S11330jir-4-039
- Menu P, Vince JE (2011) The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. *Clin Exp Immunol* 166(1):1–15. doi:10.1111/j.1365-2249.2011.04440.x
- Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Bybee A, Gaudet R, Woo P, Feighery C, Cotter

- FE, Thome M, Hitman GA, Tschopp J, McDermott MF (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. *Arthritis Rheum* 46(9):2445–2452. doi:10.1002/art.10509
27. Schoultz I, Verma D, Halfvarsson J, Torkvist L, Fredrikson M, Sjoqvist U, Lordal M, Tysk C, Lerm M, Soderkvist P, Soderholm JD (2009) Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. *Am J Gastroenterol* 104(5):1180–1188. doi:10.1038/ajg.2009.29ajg200929
  28. Pontillo A, Vendramin A, Catamo E, Fabris A, Crovella S (2011) The missense variation Q705K in CIAS1/NALP3/NLRP3 gene and an NLRP1 haplotype are associated with celiac disease. *Am J Gastroenterol* 106(3):539–544. doi:10.1038/ajg.2010.474ajg2010474
  29. Roberts RL, Topless RK, Phipps-Green AJ, Geary RB, Barclay ML, Merriman TR (2010) Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. *Genes Immun* 11(4):351–356. doi:10.1038/gene.2010.11
  30. Pontillo A, Brandao L, Guimaraes R, Segat L, Araujo J, Crovella S (2010) Two SNPs in NLRP3 gene are involved in the predisposition to type-1 diabetes and celiac disease in a pediatric population from northeast Brazil. *Autoimmunity* 43(8):583–589. doi:10.3109/08916930903540432
  31. Kastbom A, Verma D, Eriksson P, Skogh T, Wingren G, Soderkvist P (2008) Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). *Rheumatology (Oxford)* 47(4):415–417. doi:10.1093/rheumatology/kem372
  32. Myles A, Aggarwal A (2013) Lack of association of single nucleotide polymorphisms in toll-like receptors 2 and 4 with enthesitis-related arthritis category of juvenile idiopathic arthritis in Indian population. *Rheumatol Int* 33(2):417–421. doi:10.1007/s00296-012-2396-2
  33. Lamb R, Zeggini E, Thomson W, Donn R (2005) Toll-like receptor 4 gene polymorphisms and susceptibility to juvenile idiopathic arthritis. *Ann Rheum Dis* 64(5):767–769. doi:10.1136/ard.2004.026930
  34. van der Paardt M, Crusius JB, de Koning MH, Morre SA, van de Stadt RJ, Dijkmans BA, Pena AS, van der Horst-Bruinsma IE (2005) No evidence for involvement of the toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. *Ann Rheum Dis* 64(2):235–238. doi:10.1136/ard.2004.021105
  35. Gergely P Jr, Blazsek A, Weiszhar Z, Pazar B, Poor G (2006) Lack of genetic association of the toll-like receptor 4 (TLR4) Asp299Gly and Thr399Ile polymorphisms with spondylarthropathies in a Hungarian population. *Rheumatology (Oxford)* 45(10):1194–1196. doi:10.1093/rheumatology/ke062
  36. Adam R, Sturrock RD, Gracie JA (2006) TLR4 mutations (Asp299Gly and Thr399Ile) are not associated with ankylosing spondylitis. *Ann Rheum Dis* 65(8):1099–1101. doi:10.1136/ard.2005.045476
  37. Na KS, Kim TH, Rahman P, Peddle L, Choi CB, Inman RD (2008) Analysis of single nucleotide polymorphisms in toll-like receptor 4 shows no association with ankylosing spondylitis in a Korean population. *Rheumatol Int* 28(7):627–630. doi:10.1007/s00296-007-0490-7
  38. Snelgrove T, Lim S, Greenwood C, Peddle L, Hamilton S, Inman R, Rahman P (2007) Association of toll-like receptor 4 variants and ankylosing spondylitis: a case-control study. *J Rheumatol* 34(2):368–370
  39. Kilding R, Akil M, Till S, Amos R, Winfield J, Iles MM, Wilson AG (2003) A biologically important single nucleotide polymorphism within the toll-like receptor-4 gene is not associated with rheumatoid arthritis. *Clin Exp Rheumatol* 21(3):340–342
  40. Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, Martin J (2004) Polymorphisms of toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. *Tissue Antigens* 63(1):54–57
  41. Alvarez-Rodriguez L, Lopez-Hoyos M, Beares I, Mata C, Garcia-Unzueta M, Calvo-Alen J, Blanco R, Aurrecochea E, Tripathi G, Martinez-Taboada VM (2011) Toll-like receptor 4 gene polymorphisms in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. *Clin Exp Rheumatol* 29(5):795–800
  42. Jaen O, Petit-Teixeira E, Kirsten H, Ahnert P, Semerano L, Pierlot C, Cornelis F, Boissier MC, Falgarone G (2009) No evidence of major effects in several toll-like receptor gene polymorphisms in rheumatoid arthritis. *Arthritis Res Ther* 11(1):R5. doi:10.1186/ar2589ar2589
  43. Yuan M, Xia J, Ma L, Xiao B, Yang Q (2010) Lack of the toll-like receptor 4 gene polymorphisms Asp299Gly and Thr399Ile in a Chinese population. *Int J Neurosci* 120(6):415–420. doi:10.3109/00207451003778736
  44. Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Goke B, Lohse P, Ochsenkuhn T (2005) The role of toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. *Inflamm Bowel Dis* 11(7):645–652
  45. Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis A, Ikonomopoulos J, Gorgoulis VG (2005) Association between polymorphisms in the toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. *World J Gastroenterol* 11(5):681–685
  46. Hume GE, Fowler EV, Doecke J, Simms LA, Huang N, Palmieri O, Griffiths LR, Florin TH, Annese V, Radford-Smith GL (2008) Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population. *Inflamm Bowel Dis* 14(5):585–590. doi:10.1002/ibd.20362
  47. Figueroa C, Peralta A, Herrera L, Castro P, Gutierrez A, Valenzuela J, Aguillon JC, Quera R, Hermoso MA (2006) NOD2/CARD15 and toll-like 4 receptor gene polymorphism in Chilean patients with inflammatory bowel disease. *Eur Cytokine Netw* 17(2):125–130
  48. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Moutkaroudi M, Izagirre N, Syafruddin D, Kibiki G, Cristea T, Hijmans A, Hamann L, Israel S, ElGhazali G, Troye-Blomberg M, Kumpf O, Maiga B, Dolo A, Doumbo O, Hermsen CC, Stalenhoef AF, van Crevel R, Brunner HG, Oh DY, Schumann RR, de la Rua C, Sauerwein R, Kullberg BJ, van der Ven AJ, van der Meer JW, Netea MG (2007) TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. *Proc Natl Acad Sci U S A* 104(42):16645–16650. doi:10.1073/pnas.0704828104
  49. De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D (2005) Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of toll-like receptor 2 and toll-like receptor 4 in spondylarthropathy. *Arthritis Rheum* 52(7):2146–2158. doi:10.1002/art.21155
  50. Jacques P, Elewaut D (2008) Joint expedition: linking gut inflammation to arthritis. *Mucosal Immunol* 1(5):364–371. doi:10.1038/mi.2008.24mi200824
  51. Mielants H, Veys EM, Cuvelier C, De Vos M (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. *Baillieres Clin Rheumatol* 10(1):147–164
  52. Cai Y, Peng YH, Tang Z, Guo XL, Qing YF, Liang SH, Jiang H, Dang WT, Ma Q, He C, Zhou JG (2014) Association of toll-like receptor 2 polymorphisms with gout. *Biomed Rep* 2(2):292–296. doi:10.3892/br.2014.224br-02-02-0292



53. Cosan F, Oku B, Cakiris A, Duymaz-Tozkir J, Mercanoglu F, Saruhan-Direskeneli G, Ustek D, Gul A (2009) No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Behcet's disease. *Clin Rheumatol* 28(12):1385–1388. doi:[10.1007/s10067-009-1252-6](https://doi.org/10.1007/s10067-009-1252-6)
54. Soyulu A, Ates H, Cingoz S, Turkmen M, Demir BK, Tunca M, Sakizli M, Cirit M, Ersoy R, Ulgenalp A, Kavukcu S (2011) TLR polymorphisms in FMF: association of TLR-2 (Arg753Gln) and TLR-4 (Asp299Gly, Thre399Ile) polymorphisms and myeloid cell TLR-2 and TLR-4 expression with the development of secondary amyloidosis in FMF. *Inflammation* 34(5):379–387. doi:[10.1007/s10753-010-9245-9](https://doi.org/10.1007/s10753-010-9245-9)
55. Ozen S, Berdeli A, Turel B, Kutlay S, Yalcinkaya F, Arici M, Besbas N, Bakkaloglu A, Yilmaz E (2006) Arg753Gln TLR-2 polymorphism in familial mediterranean fever: linking the environment to the phenotype in a monogenic inflammatory disease. *J Rheumatol* 33(12):2498–2500
56. Yang CA, Huang ST, Chiang BL (2014) Association of NLRP3 and CARD8 genetic polymorphisms with juvenile idiopathic arthritis in a Taiwanese population. *Scand J Rheumatol* 43(2):146–152. doi:[10.3109/03009742.2013.834962](https://doi.org/10.3109/03009742.2013.834962)
57. Kastbom A, Klingberg E, Verma D, Carlsten H, Forsblad-d'Elia H, Wesamaa J, Cedergren J, Eriksson P, Soderkvist P (2013) Genetic variants in CARD8 but not in NLRP3 are associated with ankylosing spondylitis. *Scand J Rheumatol* 42(6):465–468. doi:[10.3109/03009742.2013.779020](https://doi.org/10.3109/03009742.2013.779020)
58. Sahdo B, Fransen K, Asfaw Idosa B, Eriksson P, Soderquist B, Kelly A, Sarndahl E (2013) Cytokine profile in a cohort of healthy blood donors carrying polymorphisms in genes encoding the NLRP3 inflammasome. *PLoS One* 8(10):e75457. doi:[10.1371/journal.pone.0075457](https://doi.org/10.1371/journal.pone.0075457)
59. Verma D, Sarndahl E, Andersson H, Eriksson P, Fredrikson M, Jonsson JI, Lerm M, Soderkvist P (2012) The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1beta and IL-18 production. *PLoS One* 7(4):e34977. doi:[10.1371/journal.pone.0034977](https://doi.org/10.1371/journal.pone.0034977)